Tessera
Folgen

Mike Waring

@mikewaring.bsky.social

Professor of Medicinal Chemistry at Newcastle University and Cancer Research Horizons, Director of MoSMed CDT and Editor-in-Chief of RSC Medicinal Chemistry

17 Posts341 Follower103 Folgt
Mike Waring@mikewaring.bsky.social · 8mo ago

New paper out in J Med Chem showing that covalent targeting of C775 has the potential to treat osimertinib resistant lung cancer. Really proud of this work and the team that did it! @nudrugdiscovery.bsky.social @nucancer.bsky.social @crhorizons.bsky.social pubs.acs.org/doi/10.1021/...

Covalent Alkynylpyridopyrimidinones Targeting Cysteine 775 of the Epidermal Growth Factor Receptor Overcome Resistance to Current Therapies

Inhibitors of epidermal growth factor receptor (EGFR) kinase activity are clinically effective treatments for lung cancers driven by activating mutations in EGFR. Resistance to inhibitors develops ove...

pubs.acs.org

Mike Waring@mikewaring.bsky.social · last yr.

New paper: We've always used TPGS in our micellar #DEL synthesis. This paper shows you can find better ones using @baonguyengroup.bsky.social surfactant map. Great work from Jake Odger et al pubs.rsc.org/en/Content/A...

Improvements in micelle promoted DNA-encoded library synthesis by surfactant optimisation

DNA-encoded libraries are increasingly important in hit identification at the early stage of the drug discovery process. The approach relies on efficient methods for synthesis of drug-like compounds a...

pubs.rsc.org

Mike Waring@mikewaring.bsky.social · last yr.

New paper published today describing some SAR on EGFR inhibitors including an interesting effect of a pair of enantiomers on covalent biinding www.nature.com/articles/s42...

Factors affecting irreversible inhibition of EGFR and influence of chirality on covalent binding - Communications Chemistry

Covalent inhibitors are a successful class of drugs, however, the optimization of targeted covalent inhibitors has challenges due to the need to increase non-covalent interactions and modulate reactiv...

nature.com

Mike Waring@mikewaring.bsky.social · last yr.

We have a PhD studentship in the @nudrugdiscovery.bsky.social @chemistryncl.bsky.social with me and @hannahstewart92.bsky.social to develop methods of making macrocycles as a new class of antimicrobial agents. Apply at the link and contact us if you have questions. www.findaphd.com/phds/project...

A Build-couple-transform approach to diverse macrocyclic libraries for antimicrobial drug discovery. at Newcastle University on FindAPhD.com

PhD Project - A Build-couple-transform approach to diverse macrocyclic libraries for antimicrobial drug discovery. at Newcastle University, listed on FindAPhD.com

findaphd.com

CRUK Newcastle Drug Discovery Group@nudrugdiscovery.bsky.social · 2y ago

Read about our potential breakthrough in oncology - restoring wild type p53 function with ASTX295. This molecule was co-developed with Astex Pharmaceuticals, and is currently showing great phase I trial readout! #cancer #medchem #clinicaltrials www.linkedin.com/posts/cancer...

Cancer Research Horizons on LinkedIn: #onmyhorizon #cancerresearch

2024 milestones worth celebrating 🧬🌟 Bravo to the incredible researchers at the Drug Discovery Unit at Newcastle University. They've unlocked a potential…

linkedin.com

Ute Jungwirth@utejungwirth.bsky.social · 2y ago

Exciting collaboration from our @nudrugdiscovery.bsky.social team @newcastleuni.bsky.social, @crhorizons.bsky.social and @diamondlightsource.bsky.social to accelerate hit discovery with structure-based drug design. Big shout out to our structural biology team led by Jane Endicott & Martin Noble!🙌

CRUK Newcastle Drug Discovery Group@nudrugdiscovery.bsky.social · 2y ago

Thrilled to share the new collaboration between @diamondlightsource.bsky.social + @crhorizons.bsky.social + @newcastleuni.bsky.social to accelerate structure-based drug development via fragment screening! More here: bit.ly/4g7Et3f 🧬🧶 #chemsky #chembio We're already hard at work on exciting targets 💪

CRUK Newcastle Drug Discovery Group@nudrugdiscovery.bsky.social · 2y ago

Our multidisciplinary team, with strong industry links, specialises in structural fragment-based approaches for class-leading cancer drug discovery complemented by our strengths in synthetic chemistry, innovative target validation technologies & hit matter finding. research.ncl.ac.uk/drugdiscovery/

Cancer Research Horizons Newcastle University | Cancer Research Horizons Newcastle University | Newcastle University

research.ncl.ac.uk